Leena Tiainen1,2, Minna Tanner3,2, Outi Lahdenperä4, Pia Vihinen4, Arja Jukkola5, Peeter Karihtala5, Niina Paunu2, Teppo Huttunen6, Pirkko-Liisa Kellokumpu-Lehtinen3,2. 1. Department of Oncology, School of Medicine, University of Tampere, Tampere, Finland leena.tiainen@pshp.fi. 2. Department of Oncology, Tampere University Hospital, Tampere, Finland. 3. Department of Oncology, School of Medicine, University of Tampere, Tampere, Finland. 4. Department of Oncology, Turku University Central Hospital, Turku, Finland. 5. Department of Oncology and Radiotherapy, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland. 6. Oy 4Pharma Ltd, Turku, Finland.
Abstract
AIM: The study evaluated the efficacy of bevacizumab combined with a taxane-based treatment for advanced breast cancer. PATIENTS AND METHODS: In this non-randomized phase II study 65 patients received 10 mg/kg bevacizumab i.v. (days 1 and 15, q4w) plus either 50 mg/m2 docetaxel (days 1 and 15, q4w) or 90 mg/m2 paclitaxel (days 1,8 and 15, q4w) i.v. until disease progression, maximal response, unacceptable toxicity or the withdrawal of consent. Patients without progression continued bevacizumab at 15 mg/kg i.v. (q3w) alone, or with endocrine therapy. (NCT00979641). RESULTS: Progression-free survival was 11.3 months (95% confidence interval=9.7-16.0 months) and overall survival was 35.1 months (95% confidence interval=22.2-50.3 months). More than half of the patients (62%) responded at least partially. Bevacizumab-related serious adverse events occurred in 10.8% patients and one patient died because of gastrointestinal perforation. CONCLUSION: Treating advanced breast cancer with a bevacizumab-containing regimen as the first-line cytotoxic treatment resulted in excellent response rates and long survival. Copyright
AIM: The study evaluated the efficacy of bevacizumab combined with a taxane-based treatment for advanced breast cancer. PATIENTS AND METHODS: In this non-randomized phase II study 65 patients received 10 mg/kg bevacizumab i.v. (days 1 and 15, q4w) plus either 50 mg/m2 docetaxel (days 1 and 15, q4w) or 90 mg/m2 paclitaxel (days 1,8 and 15, q4w) i.v. until disease progression, maximal response, unacceptable toxicity or the withdrawal of consent. Patients without progression continued bevacizumab at 15 mg/kg i.v. (q3w) alone, or with endocrine therapy. (NCT00979641). RESULTS: Progression-free survival was 11.3 months (95% confidence interval=9.7-16.0 months) and overall survival was 35.1 months (95% confidence interval=22.2-50.3 months). More than half of the patients (62%) responded at least partially. Bevacizumab-related serious adverse events occurred in 10.8% patients and one patient died because of gastrointestinal perforation. CONCLUSION: Treating advanced breast cancer with a bevacizumab-containing regimen as the first-line cytotoxic treatment resulted in excellent response rates and long survival. Copyright
Authors: Joyce O'Shaughnessy; Christine Brezden-Masley; Marina Cazzaniga; Tapashi Dalvi; Graham Walker; James Bennett; Shozo Ohsumi Journal: Breast Cancer Res Date: 2020-10-27 Impact factor: 6.466